🟢 Ionis Pharmaceuticals is trading 4.3% up in pre-market; catalyst remains uncertain

Ionis Pharmaceuticals is trading 4.3% up in pre-market at $46.83, with no clear catalyst identified.

• No new company-specific announcement was identified for September 22, 2026.
• The FDA approved ZANVASTRO on September 3, 2026, but the release did not report a stock-price reaction or link the approval to today’s move.
• Broader markets are mixed, offering limited macro support; the catalyst remains uncertain and may warrant rechecking later.